Immune Globulin Intravenous (Human)
( DrugBank: - / KEGG DRUG: - )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
65 | 原発性免疫不全症候群 | 14 |
65. 原発性免疫不全症候群
臨床試験数 : 500 / 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217
Showing 1 to 10 of 14 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04346108 (ClinicalTrials.gov) | August 11, 202020200811 | 10/4/202020200410 | A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID) A Study of Immune GlobulinSubcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants Wi ... | A Phase 3, Open-label, Non-controlled, Multi-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability, and Efficacy of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Subjects With Primary Immunodeficiency Diseases (PID) A Phase 3, Open-label, Non-controlled, Multi-dose Study to Evaluate the Pharmacokinetics, Safety and ... | Primary Immunodeficiency Diseases (PID) | Biological: Immune Globulin Intravenous (IGIV);Biological: Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%) Biological: Immune Globulin Intravenous(IGIV);Biological: Immune GlobulinSubcutaneous, 20% Solution ... | Baxalta now part of Shire | NULL | Completed | 2 Years | N/A | All | 17 | Phase 3 | Japan |
2 | NCT02269163 (ClinicalTrials.gov) | January 26, 201620160126 | 16/10/201420141016 | Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10% | A Phase 3, Multicenter, Open-Label Study of the Safety, Tolerability, Efficacy, and PK of ProMetic BioTherapeutics IGIV (Human) 10% in Adults and Children With Primary Immunodeficiency Diseases A Phase 3, Multicenter, Open-Label Study of the Safety, Tolerability, Efficacy, and PK of ProMetic B ... | Primary Immunodeficiency | Biological: Immune Globulin Intravenous;Biological: Prometic's Immune Globulin Intravenous 10% | Prometic Biotherapeutics, Inc. | Atlantic Research Group | Completed | 2 Years | 80 Years | All | 82 | Phase 3 | United States |
3 | NCT01218438 (ClinicalTrials.gov) | January 201320130100 | 8/10/201020101008 | Phase 2/3 Study of IGSC, 20% in PIDD | A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD) A Clinical Study of Immune GlobulinSubcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation ... | Primary Immunodeficiency Diseases (PID) | Biological: Immune Globulin Intravenous (Human), 10% Solution;Drug: Immune Globulin Subcutaneous (Human), 20% Solution Biological: Immune Globulin Intravenous (Human), 10% Solution;Drug: Immune GlobulinSubcutaneous (Hum ... | Baxalta now part of Shire | NULL | Completed | 2 Years | N/A | All | 86 | Phase 2/Phase 3 | United States;Canada |
4 | NCT01406470 (ClinicalTrials.gov) | September 201120110900 | 26/7/201120110726 | Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficien ... | An Open-Label, Single-Arm, Historically Controlled, Prospective, Multicenter Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Immune Globulin Intravenous (Human) IVIG-SN™ in Subjects With Primary Immunodeficiency An Open-Label, Single-Arm, Historically Controlled, Prospective, Multicenter Phase III Study to Eval ... | Immunologic Deficiency Syndrome | Drug: Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™ | Green Cross Corporation | Atlantic Research Group | Completed | 2 Years | 70 Years | Both | 45 | Phase 3 | United States;Canada |
5 | NCT01412385 (ClinicalTrials.gov) | June 20, 201120110620 | 8/8/201120110808 | Immune Globulin Subcutaenous (Human), 20% | A Clinical Study of Immune Globulin Subcutaneous (Human) (IGSC), 20% for the Evaluation of Efficacy, Safety, and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases A Clinical Study of Immune GlobulinSubcutaneous (Human)(IGSC), 20% for the Evaluation of Efficacy, S ... | Primary Immunodeficiency Diseases (PID) | Biological: Immune Globulin Subcutaneous (Human), 20%;Biological: Immune Globulin Intravenous (Human), 10%;Biological: Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin) Biological: Immune GlobulinSubcutaneous (Human), 20%;Biological: Immune Globulin Intravenous (Human) ... | Baxalta now part of Shire | NULL | Completed | 2 Years | N/A | All | 55 | Phase 2/Phase 3 | Austria;Germany;Hungary;Sweden;United Kingdom |
6 | NCT00814320 (ClinicalTrials.gov) | December 18, 200820081218 | 23/12/200820081223 | Gammagard Liquid and rHuPH20 in PID | Efficacy, Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human), 10% (GAMMAGARD LIQUID/KIOVIG) Administered Intravenously or Subcutaneously Following Administration of Recombinant Human Hyaluronidase (rHuPH20) in Subjects With Primary Immunodeficiency Diseases Efficacy, Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human), 10% (G ... | Primary Immunodeficiency Diseases (PID) | Biological: Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV) | Baxalta now part of Shire | NULL | Completed | 2 Years | N/A | All | 89 | Phase 3 | United States;Canada |
7 | NCT00634569 (ClinicalTrials.gov) | May 200820080500 | 5/3/200820080305 | Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects | Evaluation of the Efficacy and Safety of Flebogamma 5% DIF [Immune Globulin Intravenous (Human)] for Replacement Therapy in Pediatric Subjects With Primary Immunodeficiency Diseases. Evaluation of the Efficacy and Safety of Flebogamma 5% DIF [Immune Globulin Intravenous (Human)] for ... | Primary Immune Deficiency Disease | Biological: Flebogamma 5% DIF | Instituto Grifols, S.A. | NULL | Completed | 2 Years | 16 Years | All | 24 | Phase 4 | United States |
8 | NCT00546871 (ClinicalTrials.gov) | October 3, 200720071003 | 18/10/200720071018 | Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects Comparison of Intravenousand Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (P ... | Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human)10% (IGIV, 10%) Ad ... | Primary Immunodeficiency Diseases (PID) | Drug: Immune Globulin Intravenous (Human), 10% | Baxalta now part of Shire | NULL | Completed | 24 Months | N/A | All | 49 | Phase 2/Phase 3 | United States |
9 | NCT00389324 (ClinicalTrials.gov) | November 200620061100 | 17/10/200620061017 | A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immuno ... | An Open-Label Single-Sequence, Crossover Trial to Evaluate the Pharmacokinetics and Safety of Subcutaneous Gamunex® 10% (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) in Subjects With Primary Immunodeficiency An Open-Label Single-Sequence, Crossover Trial to Evaluate the Pharmacokinetics and Safety of Subcut ... | Immunologic Deficiency Syndrome | Biological: Immune Globulin Intravenous (Human) | Grifols Therapeutics Inc. | NULL | Completed | 13 Years | 75 Years | All | 35 | Phase 2 | United States;Canada |
10 | NCT00220766 (ClinicalTrials.gov) | August 200220020800 | 13/9/200520050913 | Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients | IGIV-C 10% Rapid Infusion Trial in Primary Immune Deficient Patients | Immunologic Deficiency Syndrome;Agammaglobulinemia;Severe Combined Immunodeficiency;Wiskott-Aldrich Syndrome;Common Variable Immunodeficiency Immunologic Deficiency Syndrome;Agammaglobulinemia;Severe Combined Immunodeficiency;Wiskott-Aldrich ... | Drug: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified;Drug: Dextrose, 5% in Water Drug: Immune Globulin Intravenous[Human], 10% Caprylate/Chromatography Purified;Drug: Dextrose, 5% i ... | Grifols Therapeutics Inc. | NULL | Completed | 18 Years | 75 Years | Both | 100 | Phase 3 | United States;Canada |